AR and central nervous system cancer: In addition, the TERT promoter mutations, commonly observed in other malignancies (eg, gliomas, bladder, thyroid cancers, and melanoma), were not possible to examine in this study owing to the lack of the gene promoter coverage in the NGS panel available at the time of study.30–33 Finally, there is lack of feedback information on the usefulness of molecular profiling in the treatment of metastatic LCT with potentially actionable findings detected in our cohort (eg, overexpression of Topo1 and AR).